Metabolic Brain Disease, Journal Year: 2025, Volume and Issue: 40(5)
Published: April 17, 2025
Language: Английский
Metabolic Brain Disease, Journal Year: 2025, Volume and Issue: 40(5)
Published: April 17, 2025
Language: Английский
Brain Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 100206 - 100206
Published: Feb. 1, 2025
Language: Английский
Citations
0Nutritional Neuroscience, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 26
Published: March 3, 2025
Background: Curcumin, a polyphenolic compound derived from Curcuma longa, exhibits significant neuroprotective potential due to its diverse pharmacological properties.Objective: This review explores curcumin's role in modulating key pathological mechanisms underlying neurodegenerative disorders such as Alzheimer's, Parkinson's diseases, Amyotrophic Lateral Sclerosis, Huntington's Disease and Prion Disease.Methods: A comprehensive analysis of molecular interactions, including effects on amyloid-beta (Aβ) aggregation, tau hyperphosphorylation, neuroinflammation, oxidative stress, metal-induced neurotoxicity, was conducted. Additionally, strategies overcome low bioavailability blood-brain barrier (BBB) permeability were evaluated.Results: Curcumin inhibits Aβ aggregation promotes disaggregation, reducing amyloid plaque formation Alzheimer's disease. It modulates glial cell activity, attenuating neuroinflammation fostering environment. By interacting with proteins, curcumin prevents hyperphosphorylation neurofibrillary tangle formation. As potent antioxidant, it scavenges reactive oxygen species, mitigating stress-related neuronal damage. Its metal-chelating properties further diminish neurotoxicity by sequestering iron copper ions. Despite limited BBB permeability, therapeutic efficacy can be enhanced using nanocarriers nanoparticles, liposomes, micelles, which improve solubility, stability, brain penetration.Conclusion: Curcumin's multifaceted make promising candidate for preventing or slowing disease progression. Advanced drug delivery systems hold overcoming pharmacokinetic limitations, paving the way future clinical applications.
Language: Английский
Citations
0Metabolic Brain Disease, Journal Year: 2025, Volume and Issue: 40(5)
Published: April 17, 2025
Language: Английский
Citations
0